Adverse Events in Total Artificial Heart for End-Stage Heart Failure: Insight From the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE)-Reference-Cited by-同舟云学术

Adverse Events in Total Artificial Heart for End-Stage Heart Failure: Insight From the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE)

Published:2023 Issue: Volume:5 Page:
ISSN:2636-154X
Container-title:International Journal of Heart Failure
language:en
Short-container-title:Int J Heart Fail

Author:

Tan Min Choon¹²^ORCID,Yeo Yong Hao³,Tham Jia Wei⁴,Tan Jian Liang⁵,Fong Hee Kong⁶,Tan Bryan E-Xin⁷^ORCID,Lee Kwan S¹,Lee Justin Z⁸

Affiliation:

1. Division of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.

2. Department of Internal Medicine, New York Medical College at Saint Michael’s Medical Center, Newark, NJ, USA.

3. Department of Internal Medicine, Beaumont Health, Royal Oak, MI, USA.

4. Perdana University-Royal College of Surgeons in Ireland, Kuala Lumpur, Malaysia.

5. Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

6. Division of Cardiovascular Medicine, UC Davis Medical Center, Sacramento, CA, USA.

7. Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.

8. Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.

Publisher

XMLink

Subject

General Medicine

Link

https://e-heartfailure.org/pdf/10.36628/ijhf.2023.0020

Reference28 articles.

1. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

2. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology

3. OPTN/SRTR 2016 Annual Data Report: Heart

4. Survival on the Heart Transplant Waiting List

5. Trends and outcomes following total artificial heart as bridge to transplant from the UNOS database